Vice President's Council on Competitiveness
Executive Summary
House votes (236-183) on July 1 to eliminate the staff budget of $86,000 for Vice President Quayle's council. The vote was on an amendment to the FY 1993 Treasury/General Government appropriations bill, which cleared the House later that day. A November 1991 report on ways to improve the drug approval process is one example of the council's efforts to review federal regulations and promote policies to enhance industry competitiveness, but some legislators contend the council exerts undue influence on the activities of federal agencies and lacks public accountability ("The Pink Sheet" Nov. 18, 1991, p. 4). President Bush has threatened to veto the entire spending measure unless funding is restored.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth